comparemela.com

Latest Breaking News On - Johannes bacher - Page 1 : comparemela.com

OpGen s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND

OpGen s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

OpGen s (OPGN) Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND

OpGen s (OPGN) Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

OpGen (OPGN) Submits De Novo request to the FDA for Unyvero Urinary Tract Infection Panel

OpGen (OPGN) Submits De Novo request to the FDA for Unyvero Urinary Tract Infection Panel
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

OpGen Submits De Novo request to the U S FDA for Unyvero Urinary Tract Infection Panel

18.04.2023 - Based on large multi-center study with over 1,800 patient samplesPrimary endpoint for Unyvero UTI for urinary tract infection was successfully met and shows overall weighted average sensitivity of 96.8% and overall weighted average specificity of . Seite 1

OpGen (OPGN) Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen (OPGN) Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.